Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hepatic Insufficiency: early-phase trial registry
3 of 15 indexed Hepatic Insufficiency trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 3 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Hepatic Insufficiency: 15 US clinical trials tracked, 3 recruiting.
Hepatic Insufficiency is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 6 of these trials.
Enrollment posture brief
Registry condition hepatic-insufficiency
OPEN 3 | RECR 20% | LATE 0 | EARLY 14 | RANK #1140 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Hepatic Insufficiency lists 3 open slots (20% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hepatic Insufficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hepatic Insufficiency is recruiting below its size-band peers.
3 of 15 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hepatic Insufficiency research.
Eli Lilly and Company accounts for 6 of 15 trials (40%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Hepatic Insufficiency trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 15 trials that report a genuine target (sentinel values excluded). 15 of those (100%) plan for fewer than 100 participants.
-
Hepatic Insufficiency research is mostly interventional.
15 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
X4 Pharmaceuticals
NCT06858696
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems
Boehringer Ingelheim
NCT06957756
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
Eli Lilly and Company
NCT07401862
Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency
Axcella Health
NCT04147936
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
Eli Lilly and Company
NCT06719128
Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment
Bristol-Myers Squibb
NCT00859053
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
Eli Lilly and Company
NCT05916560
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
Debiopharm International
NCT01860326
Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function
Novartis
NCT00416702
A Study of Tirzepatide in Participants With Impaired Liver Function
Eli Lilly and Company
NCT03940742
A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
Eli Lilly and Company
NCT01836185
The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)
Merck Sharp & Dohme
NCT01797536
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
Eli Lilly and Company
NCT05440344
Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
Pfizer
NCT00645021
A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NCT01186588
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
Top Sponsors
Named interventions
Most-linked intervention names on Hepatic Insufficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hepatic Insufficiency trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hepatic Insufficiency page
15 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Hepatic Insufficiency trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Hepatic Insufficiency trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatic Insufficiency condition card totals 15 registered trials; most-linked intervention AXA1665; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.